IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.246
AS - Asia 977
EU - Europa 945
SA - Sud America 340
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 3.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.199
SG - Singapore 492
BR - Brasile 303
IE - Irlanda 242
IT - Italia 217
SE - Svezia 191
CN - Cina 186
HK - Hong Kong 172
DE - Germania 64
FR - Francia 44
VN - Vietnam 38
GB - Regno Unito 34
CA - Canada 29
PL - Polonia 27
RU - Federazione Russa 27
FI - Finlandia 24
IN - India 24
AT - Austria 21
NL - Olanda 16
MX - Messico 13
AR - Argentina 12
JP - Giappone 12
BD - Bangladesh 9
ZA - Sudafrica 9
EC - Ecuador 8
PK - Pakistan 6
TR - Turchia 6
BE - Belgio 5
ES - Italia 5
ID - Indonesia 5
IQ - Iraq 5
JO - Giordania 5
LT - Lituania 5
MA - Marocco 5
PY - Paraguay 5
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CL - Cile 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
KE - Kenya 3
KZ - Kazakistan 3
NO - Norvegia 3
UA - Ucraina 3
UZ - Uzbekistan 3
BY - Bielorussia 2
EE - Estonia 2
NZ - Nuova Zelanda 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BW - Botswana 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LK - Sri Lanka 1
NI - Nicaragua 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.537
Salva come PNG Salva come JPEG
Città #
Dublin 240
Ashburn 210
Singapore 204
Hong Kong 172
Chandler 169
Dallas 139
Nyköping 94
Beijing 62
Messina 57
Los Angeles 49
Princeton 37
Medford 33
Munich 30
São Paulo 25
Des Moines 24
New York 21
Redondo Beach 20
Buffalo 19
Seattle 15
Moscow 14
The Dalles 14
Vienna 14
Ann Arbor 13
Ho Chi Minh City 13
London 13
Milan 13
Catania 11
Frankfurt am Main 11
Hanoi 11
Tokyo 11
Atlanta 10
Lauterbourg 10
Nuremberg 10
Stockholm 10
Warsaw 10
Amsterdam 9
Brooklyn 9
Chennai 9
Denver 9
Jinan 9
Montreal 8
Rome 8
Council Bluffs 7
Curitiba 7
Dearborn 7
Lappeenranta 7
Mexico City 7
Porto Alegre 7
Rio de Janeiro 7
Santa Clara 7
Turku 7
Boston 6
Campinas 6
Changsha 6
Jacksonville 6
Nanjing 6
Pozzuolo Martesana 6
San Francisco 6
Toronto 6
Turin 6
Wilmington 6
Amman 5
Belo Horizonte 5
Brussels 5
Düsseldorf 5
Hebei 5
Helsinki 5
Johannesburg 5
Orem 5
Phoenix 5
Tianjin 5
Brasília 4
Cagliari 4
Chicago 4
Guayaquil 4
Haikou 4
Hangzhou 4
Jakarta 4
Manchester 4
Mumbai 4
Palermo 4
Pelotas 4
Pune 4
Shenyang 4
Vitória da Conquista 4
Zhengzhou 4
Aracaju 3
Bogotá 3
Bremen 3
Cambridge 3
Caratinga 3
Cariacica 3
Fuzhou 3
Houston 3
Lahore 3
Manaus 3
Mineo 3
Nairobi 3
Ningbo 3
Osasco 3
Totale 2.144
Salva come PNG Salva come JPEG
Nome #
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 125
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 117
Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study 104
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 104
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 101
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 98
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 97
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 96
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 95
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 93
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 92
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 91
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 87
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 85
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 84
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 83
Role of IL-33/ST2 Pathway in Inflammatory Bowel Disease: An Overview and Future Perspectives 81
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 72
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 70
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 69
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 68
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 66
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 65
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 64
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 64
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 61
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 58
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 56
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 56
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 54
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 52
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 52
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 51
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 50
Incident Colorectal Cancer in Inflammatory Bowel Disease 50
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 49
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 49
Ultrasonography tight control and monitoring in crohn's disease during different biological therapies: a multicenter study 49
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 48
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 47
Defense mechanisms and inflammatory bowel diseases: a narrative review 47
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 45
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 45
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 44
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients 41
null 40
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 39
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 37
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 36
Letter: the clinical course of Crohn's disease—the Sicilian experience 36
null 33
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 33
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 31
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 31
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD) 31
Epidemiology and clinical course of late onset inflammatory bowel disease 27
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 22
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 22
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 21
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 21
Standard Therapeutic Approach and New Therapies 19
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 18
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases 17
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 16
Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction 14
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 3
Totale 3.722
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.937
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202174 0 0 0 0 0 4 18 5 5 19 16 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023597 39 65 26 53 29 45 14 28 268 11 13 6
2023/2024256 20 29 36 54 14 23 7 15 0 33 8 17
2024/20251.244 16 21 16 79 60 76 94 194 271 79 133 205
2025/20261.119 156 145 216 227 339 36 0 0 0 0 0 0
Totale 3.722